Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of ...

A University of Kentucky Markey Cancer Center study shows that a targeted form of radiation therapy can be safely delivered ...

—Building on earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer, plus identify factors ...

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...